Skip to main content

Table 3 logistic regression analysis of clinical and laboratory variables associated to a MMSE < 24 and to a RHI > 1.6 in subjects with diabetic foot

From: Metabolic memory in diabetic foot syndrome (DFS): MICRO-RNAS, single nucleotide polymorphisms (SNPs) frequency and their relationship with indices of endothelial function and adipo-inflammatory dysfunction

Parameter estimates

MMSE SCOREa

B

Std. Error

Wald

df

P

Exp(B)

95% Confidence Interval for Exp(B)

Lower bound

Upper bound

Intercept

1.317

5.034

0.068

1

0.794

   

Sex

0.302

0.908

0.111

1

0.739

1.353

0.228

8.025

Age

0.095

0.054

3.041

1

0.081

1.099

0.988

1.223

SBP

− 0.063

0.038

2.655

1

0.103

0.939

0.871

1.013

DBP

0.021

0.039

0.300

1

0.584

1.022

0.946

1.103

BMI

− 0.082

0.065

1.589

1

0.208

0.922

0.812

1.046

Hypertension

2.666

1.208

4.873

1

0.027

14.386

1.348

153.499

CV Events

− 0.116

0.887

0.017

1

0.896

0.890

0.157

5.063

Stroke

2.582

1.259

4.202

1

0.040

13.218

1.120

156.029

Dyslipidemia

1.795

0.998

3.234

1

0.072

6.021

0.851

42.603

HbA1c:

0.012

0.241

0.003

1

0.959

1.012

0.632

1.622

Smoke

0.395

0.793

0.248

1

0.618

1.484

0.314

7.023

Beta-blockers

− 1.282

0.951

1.814

1

0.178

0.278

0.043

1.792

Calcium antagonist

− 0.842

1.000

0.710

1

0.400

.431

0.061

3.057

ACE I/ ARBs

− 0.544

0.854

0.405

1

0.524

.581

0.109

3.098

Statins

− 0.111

0.857

0.017

1

0.897

o.895

o.167

4.805

Antiplatelets

− 0.038

0.985

0..002

1

0.969

0.962

0.140

6.635

GLP1 A/Anti-DPP4

− 0.625

1.113

0.316

1

0.574

0.535

0.060

4.737

Sulfonylureas

− 1.331

1.727

0.594

1

0.441

0.264

0.009

7.798

Metformin

− 3.469

1.674

4.294

1

0.038

0.031

0.001

0.829

Insulin

0.086

1.090

0.006

1

0.937

1.089

00.129

9.229

RHI

        

Parameter estimates

RHISCOREa

B

Std. Error

Wald

df

Sig

Exp(B)

95% Confidence Interval for Exp(B)

Lower bound

Upper bound

0

Intercept

− 3.277

6.112

0.287

1

0.592

   

Sex

− 0.014

1.114

0.000

1

0.990

0.986

0.111

8.759

Age

0.0003

0.048

0.005

1

0.943

1.003

0.913

1.102

SBP

0.080

0.048

2.815

1

0.093

1.083

0.987

1.190

DBP

− 0.035

0.049

0.519

1

0.471

0.966

0.878

1.062

BMI

− 0.009

0.073

0.016

1

0.900

0.991

0.859

1.143

Ipertension

− 0.216

0.140

2.387

1

0.122

0.806

0.612

1.060

CV Events

1.112

1.161

0.918

1

0.338

0. 329

0.034

3.202

Stroke

1.089

1.146

0.904

1

0.342

2.973

0.315

28.067

Dyslipidemia

1.394

1.557

0.802

1

0.371

0.248

0.012

5.249

HbA1c:

1.150

0.926

1.543

1

0.214

0.317

0.052

1.944

Smoke

0.026

0.269

0.009

1

0.922

0.974

0.575

1.651

Intercept

0.497

0.959

0.269

1

0.604

1.644

0.251

10.763

Beta-blockers

0.566

0.974

0.338

1

0.561

1.762

0.261

11.883

Calcium antagonist

0.305

1.103

0.076

1

0.782

1.356

0.156

11.773

ACE I/ ARBs

− 0.108

1.166

0.009

1

0.926

0.898

0.091

8.827

Statins

1.139

1.079

1.115

1

0.291

3.124

0.377

25.871

Antiplatelets

− 1.016

1.200

0.717

1

0.397

0.362

0.034

3.801

GLP1 A/Anti-DPP4

− 1.006

0.964

1.089

1

0.297

0.366

0.055

2.419

Sulfonylureas

− 2.289

1.717

1.778

1

0.182

0.101

0.004

2.932

Metformin

1.220

1.281

0.908

1

0.341

3.389

0.275

41.735

Insulin

0.183

1.157

0.025

1

0.874

1.201

0.124

11.598

  1. a. The reference category is: control subjects
  2. SBP: systolic blood pressure; DBP: diastolic blood pressure; CV events: cardiovascular events; BMI: body mass index; RHI: reactive hyperaemia index; MMSE: mini-mental state examination; HbA1c: glycated haemoglobin; ACE-inh/ARBs: ACE-inhbitors/ angiotensin receptor blockers; GLP1-ra: GLP-1 receptor agonist; DPP-4 inh: DPP-4 inh: dipeptidyl peptidase-4 inhibitors